







































2574-0954 Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. DOI: 10.1097/XCE.0000000000000250
This is an open-access article distributed under the terms of the Creative 
Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-
NC-ND), where it is permissible to download and share the work provided it is 
properly cited. The work cannot be changed in any way or used commercially 
without permission from the journal.
Recalibration of thinking about adrenocortical function 
assessment: how the ‘random’ cortisol relates to the short 
synacthen test results
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Background The short synacthen test (SST) is the 
most commonly performed investigation to assess 
adrenal function. Appropriate criteria for when an SST is 
performed are subject to debate. We investigated how 
random serum cortisol levels relate to SST response.
Methods We examined random cortisol measurements 
taken between 04.40–23.55 p.m. results of SST baseline 
and 30-/60-min cortisol performed over 12 months (225 
SSTs) at Salford Royal Hospital. Serum cortisol was 
measured on the Siemens Centaur Analyser.
A 30–60-min cortisol concentration of ≥450 nmol/L 
defined a pass; 350–449 nmol/L defined borderline.
Results Patients only proceeded to SST if random 
cortisol was <400 nmol/L. For those not on corticosteroids 
for at least 2 weeks, 42/43 (97.7%) cases with random 
cortisol concentration of ≥200 nmol/L had an SST ‘pass’. 
The relation was less clear with corticosteroid treatment 
(19/35 cases; 54%).
For those not taking glucocorticoid treatment (including 
inhaled/topical corticosteroids) in the previous 2 weeks, 
91.8% of SSTs were pass/2.7% borderline/5.5% fail. For 
those on steroids, 51.9% of SSTs were a pass/11.4% were 
borderline.
In relation to the postsynacthen cortisol pass cut-off 
of ≥450 nmol/L, in 15/207 (7.2%) of cases, the 60-min 
cortisol was ≥450 nmol/L (adequate adrenocortical 
function), but 30-min cortisol was below this. In all cases 
where the 30-min cortisol did indicate a pass (i.e. was 
≥450 nmol/L) the 60-min cortisol was also ≥450 nmol/L.
Conclusion Our findings suggest that if the random 
cortisol level is ≥200 nmol/L, regardless of the time of day 
and the person was not taking corticosteroid treatment 
in the previous 2 weeks, SST may not be needed. Our 
data also suggests that 60-min cortisol retains utility. 
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Introduction
Primary adrenal insufficiency is caused by the failure of 
the adrenal glands to produce physiological amounts of 
cortisol and aldosterone. This can be a consequence of 
pituitary insufficiency or suppression of endogenous cor-
tisol production as a result of taking exogenous steroids 
for a prolonged period.
The signs and symptoms associated with adrenal insuffi-
ciency, such as chronic exhaustion, fatigue, muscle weak-
ness and weight loss [1], are often nonspecific. Adrenal 
insufficiency may cause changes in serum electrolyte lev-
els, particularly low serum sodium and high serum potas-
sium, as well as acute symptoms at times of intercurrent 
illness. Elevation of blood urea and borderline anemia 
may also ensue [2].
In order to confirm the diagnosis of adrenal insufficiency, a 
short synacthen test (SST) is recommended [3], with the 
insulin tolerance test (ITT) being the gold standard in rela-
tion to the assessment of adrenocortical function [2].
The decision about whether to undertake the SST is nor-
mally taken by the clinicians looking after the individual, 
often after consultation with their local clinical labora-
tory. An SST is generally a hospital day case test, requir-
ing hospital resources in terms of specialist healthcare 
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professional oversight (and hence time), often on a day 
ward, with at least 2 h in hospital for the person undergo-
ing the test.
In the presence of an adequate morning (08:00–09:00 
a.m.) serum cortisol (generally accepted as ≥400  nmo-
l/L), an SST may not be necessary. Furthermore, a very 
low basal serum cortisol at any time (<100 nmol/L), may 
be assumed to demonstrate cortisol deficiency, thereby 
often not requiring an SST [4]. Due to variation between 
assays [5] exact cut-offs may vary.
In this single-center study covering a 12 month period, 
we undertook to evaluate the relation between random 
cortisol measurements from samples taken at various 
times of the day, and the results of the subsequent SST, 
with a view to understanding how random cortisol lev-
els taken at times throughout the day may relate to the 
biochemical response to synacthen (pass/borderline/fail) 
on the STT. Furthermore, in some centers, including our 
own a 60-min postsynacthen cortisol is measured. Here 
we looked at whether this has utility in relation to the 
assessment of adrenocortical function.
This piece of work follows on from the comprehensive 
evaluation of random cortisol vs. SST assessed adreno-
cortical function reported by Mackenzie et al. [6] in 2019. 
They found that a morning (8 a.m.–12 p.m.) serum cor-
tisol of <275  nmol/L identified subnormal-stimulated 
cortisol with 96.2% sensitivity. For afternoon (12 p.m.–6 
p.m.) samples, a cut-off of <250 nmol/L achieved 96.1% 
sensitivity for adrenocortical dysfunction.
Our aim was to understand more fully how a random cor-
tisol measurement relates to the SST results in relation 
to a history of pituitary/nonpituitary disease and recent 
corticosteroid treatment. Our hypothesis was that many 
fewer SSTs could be done if we have the right criteria for 
an SST in place.
Methods
All patients attended Salford Royal Foundation Trust 
(SRFT) for their tests. Data from 225 consecutive SSTs 
and prior cortisol measurements, including the time of 
day when the tests were performed, were obtained from 
the hospital electronic patient record (EPR). This cov-
ered a period of 12 months from mid-June 2017 to mid-
June 2018. Where there was more than one prior cortisol 
measurement, the one closest in time to the date of the 
SST was taken, where a patient had more than one SST 
following cortisol measurement the one closest in time to 
the random cortisol was taken, so as not to be including 
multiple tests on the same individual.
Serum cortisol was measured by immunoassay on the 
Siemens Centaur XP analyzer (Erlangen, Germany). All 
samples were processed at the Department of Clinical 
Biochemistry at SRFT. The analytical range of this assay 
is 13.8–2069  nmol/L. Whenever possible, a patient on 
oral corticosteroids was changed to oral hydrocortisone 
for 48 h prior to the SST being performed (if they were 
not already on this) with the omission of hydrocortisone 
on the evening before and the morning of the test or 
omission on the morning of the test if on daily predni-
solone/dexamethasone. Inhaled/transdermal corticoster-
oids were not taken/applied until after the STT but were 
taken/applied on the day before.
Demographic (age and sex) together with clinical data 
was obtained from the SRFT EPR. All data was fully 
anonymized prior to analysis by our statisticians (G.Y. 
and M.M.). History of pituitary pathology was recorded, 
as was previous pituitary surgery/conservatively man-
aged pituitary condition. History of autoimmune disor-
ders included type 1 diabetes mellitus (T1DM), primary 
hypothyroidism and connective tissue disorder were also 
documented. A full list is given in Appendix 1. All steroid 
use over the 2 weeks previous to the SST was taken into 
account and included inhaled, nasal and topical steroids.
Women taking the combined oral contraceptive pill 
(COCP) or estrogen-containing hormone replacement 
treatment (HRT) were asked to discontinue these med-
ications for 30 days prior to the SST. We analyzed results 
of SST baseline, 30- and 60-min cortisol performed over 
the 12-month period (225 SSTs) and related the results 
to the pre-SST cortisol. For 18/225 patients, the 60-min 
serum cortisol was not available.
A 30- and/or 60-min cortisol of ≥450 nmol/L was taken 
as indicative of sufficient adrenal reserve (hereafter 
defined as a ‘pass’). Failure of cortisol to reach 350 nmo-
l/L postsynacthen administration at either 30- or 60-min 
postsynacthen was taken as a definite adrenal insuffi-
ciency (hereafter defined as a ‘fail’). All other results 
(350–449  nmol/L) were defined as ‘borderline’; poten-
tially requiring further endocrine evaluation. These are 
departmentally-agreed criteria that take into account the 
performance of the Siemens cortisol assay and the find-
ings of the United Kingdom National Audit published in 
2010 [7].
This project was deemed by Salford Royal NHS 
Foundation Trust, Research and Innovation Department 
as a quality improvement (QI) project. No individual 
patient was contacted in the course of the evaluation, and 
data was fully anonymized prior to analysis. This project 
was denoted as a service evaluation exercise.
The data that we have analyzed to write this paper will 
be available to researchers in an anonymized form on 
request to the corresponding author.
All analyses were performed using StataCorp. 2015. Stata 
Statistical Software: Release 14. College Station, Texas, 
USA: StataCorp LP. The relation between random cor-
tisol and postsynacthen cortisol is illustrated by a scatter 
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diagram and Pearson (Spearman) correlation coefficient. 
Comparison of means was done either by the one-way 
analysis of variance (ANOVA) and t test or corresponding 
nonparametric tests, Kruskal–Wallis or Mann–Whitney U 




The baseline characteristics by SST result are given in Table 1. 
Age at the time of the test varied from 16.8 to 100.3 years. The 
mean age was 52.9 years (SD ± 17.8 years). A total of 65.8% of 
individuals tested were women; 81.6% of men and 83.1% of 
women were under the age of 70 years.
Of the 225 people included, 61/225 (27.1%) had a prior 
diagnosis of pituitary pathology. A total 51/225 (22.7%) 
had a history of the autoimmune disorder, including 
type 1 diabetes mellitus (T1DM), primary hypothyroid-
ism and connective tissue disorder (Appendix 1). A total 
79/225 (35.1%) reported steroid treatment in the previous 
14 days. 70/79 (88.6%) were taking systemic glucocorti-
coids (hydrocortisone, prednisolone or dexamethasone) 
(discontinued as per protocol period to the SST) and 9/79 
(11.4%) regular inhaled or nasal corticosteroids.
With regard to the healthcare setting, 54/225 (24.0%) of 
tests were carried out on inpatients and 171/225 (76.0%) 
as outpatients. None of the patients were in a critical care 
setting (high dependency unit or ICU) at the time of the 
random serum cortisol or SST.
Taking all tests into account, irrespective of medical/drug 
history, 183/225 (81.3%) of SSTs were defined as a pass, 
with 12/225 (5.3%) borderline and 30/225 (13.4%) fail.
For those not on glucocorticoid treatment (includ-
ing inhaled and topical corticosteroids) in the previous 
2 weeks, 134/146 were a pass (91.8%), 4/146 were border-
line (2.7%) and 8/146 (5.5%) were a fail.
For the 79 patients on glucocorticoid treatment, 41 
(51.9%) of SSTs were a pass, 9 (11.4%) were borderline, 
with 29 (36.7%) a fail. For those with a history of pitui-
tary disease (irrespective of corticosteroid status), 82.0% 
of SSTs were a pass and 1.6% borderline, with 16.4% fail.
For inpatient tests (54 tests), the pass rate was 77.8% (9.3% 
were borderline), while that for outpatient tests (171 tests) was 
81.3% (3.5% were borderline) (χ2 = 0.32, P = 0.571).
Relation of baseline cortisol to postsynacthen cortisol 
level
For those not on corticosteroids
We related baseline serum cortisol to 30-min cortisol 
for those individuals not on corticosteroids and with no 
known pituitary pathology. For those not on corticoster-
oids (including inhaled and topical steroids), 42/43 cases 
with a random cortisol concentration of ≥200 nmol/L had 
an SST pass (Fig. 1a). The one case where the 30-min 
postsynacthen cortisol was 334 nmolL (i.e. not a ‘pass’) 
had an adrenal adenoma.
The reason why there are very few random cortisol lev-
els more than 450 nmol/L in Fig. 1a is that our specialist 
endocrinology service advises that, unless there is clinical 
suspicion of adrenal insufficiency in cases where the ran-
dom serum cortisol is 400 nmol/L or more, an SST is not 
indicated.
The cortisol values for patients not on steroid treatment 
in the previous 2 weeks, where both 30- and 60-min SST 
values were available (n = 140), are shown in Table 2 for 
the random cortisol, 30- and 60-min postsynacthen cor-
tisol values. Random cortisol was numerically higher for 
the ‘pass’ group than ‘fail’, but because of low numbers, 
there was no statistically significant difference.
For those on corticosteroid treatment
The relation was less clear for those on corticosteroid treat-
ment, including inhaled and topical corticosteroids and those 
on a decreasing oral corticosteroid regime; for cases with ran-
dom cortisol of ≥200 nmol/L, 19/35 passed (Fig. 1b). Thus 54% 
with random cortisol of ≥200 nmol/L passed the test and 46% 
failed on the basis of the 30-min cortisol.
For those with a history of pituitary disease
For those with a history of pituitary disease, irrespective 
of prior steroid use, with random cortisol of ≥200 nmol/L, 
10/16 were a pass (Fig. 1c). For those with a history of 
pituitary disease with no recent steroid use, both patients 
passed the SST.
For none of these categories was there a lower limit of 
random cortisol below which the SST was invariably a 
‘fail’.
Random cortisol and time of the day
For ‘random’ serum cortisol measurements taken 
between 04.40–23.55 h, (Fig. 2), after 1500 h there was 
a nonstatistically significant trend for the random cortisol 
levels to be lower, that is, more readings in the higher 
than the lower range.
Utility of 30- vs. 60-min cortisol
207/225 SSTs had both a 30- and 60-min cortisol. In 
relation to the postsynacthen cortisol pass cut-off of 
≥450  nmol/L, in 15/207 (7.2%) cases, the 60-min corti-
sol was ≥450 nmol/L (adequate adrenocortical function), 
but 30-min cortisol was below this. In all cases where the 
30-min cortisol did indicate a pass (142 cases) (i.e. was 
≥450 nmol/L) the 60-min cortisol was also ≥450 nmol/L.
Age/estrogen effect
We also looked at the age of the person at the time of the 
test (≥70 vs. <70 years) for people not on corticosteroid 
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treatment. There was no decrease in baseline SST corti-
sol levels in those in the older age category. A total of 12 
women patients were on the combined oral contraceptive 
pill (COCP) (n = 3) or hormone replacement treatment 
(HRT) (n = 9). All discontinued the COCP or HRT for 
30 days prior to the SST.
Discussion
Our findings on the basis of observational data suggest 
that if the random cortisol level (at any time of the day) 
is ≥200 nmol/L, and the person was not on corticosteroid 
treatment in the previous 2 weeks, there may be no need 
to perform an SST unless a specific evaluation is required 
(this does not apply if the woman is taking the COCP 
or estrogen-containing HRT at the time of the random 
cortisol given the potential for cortisol binding globulin 
and so total serum cortisol to be increased in such circum-
stances). We accept that this paper reports what should 
be seen as a ‘quasivalidation’ study. Furthermore, the 
60-min cortisol appears to have utility, as it enables some 
people to avoid further testing.
We are not suggesting here that our findings lead to any 
change in practice. Rather we aim to contribute to the 
debate concerning (1) when an SST needs to be arranged 
and (2) whether the 60-min level offers additional value.
In the large study by Mackenzie et al. [6] there was sug-
gested guidance with regard to the interpretation of random 
cortisol and decisions regarding further testing. In this study, 
we have added a differentiation on the basis of recent corti-
costeroid use while also examining the utility of the 60-min 
SST cortisol in order to rule out a proportion of people as 
having at least partial adrenal insufficiency.
Our findings suggest that if the random cortisol level is 
≥200  nmol/L and the person was not on corticosteroid 
treatment in the previous 2 weeks, there may be no need 
to perform an SST. This particularly applies if the per-
son was not an inpatient at the time of the random cor-
tisol, and therefore, not unduly physiologically stressed 
through acute/intercurrent illness. None of the patients 
were in a critical care setting when the random serum 
cortisol and SST were carried out. We do not have suffi-
cient numbers of patients with pituitary disease and not 
taking glucocorticoids to draw any conclusions.
This relation appears to hold irrespective of the time of 
day when the random sample was taken. The absence 
of any statistically significant relationship between the 
time of day of the random cortisol (i.e. cortisol levels on 
patients tested later in the day were not on the whole 
lower) and the level of random cortisol may relate to 
the circumstances of having the blood test for corti-
sol, in terms of the influence of psychological/physical 
stress on the level of random cortisol.
Many individuals on steroid treatment at the time of the 
test had random cortisol levels of ≥200 nmol/L (48.1%) 
and did not pass the SST. Assay interference by exog-
enously administered corticosteroids also needs to be 
taken into account. It is interesting that irrespective of 
steroid use, 82% of pituitary patients in our series with 
random cortisol ≥200  nmol/L had a pass on the SST. 
Raising the random cortisol threshold to ≥400  nmol/L 
meant that only one person on steroid treatment with 
random cortisol in that range failed the SST.
There was no significant difference between the propor-
tion of inpatient (77.8%) vs. outpatient SSTs (81.3%), which 
were a ‘pass’. However, given that the stress of intercurrent 
illness can cause cortisol levels to rise, it may be pertinent to 
limit the utility of the 200 nmol/L cut-point to people not on 
corticosteroids and to hospital outpatients.
A meta-analysis by Kazlauskaite et al. [5] reported that 
in the absence of exogenous glucocorticoids, a cut-off 
threshold for basal morning (0600–1000) cortisol con-
centrations of 140  nmol/L (5  g/dL) is suggestive of 
adrenal insufficiency. The diagnosis of adrenal insuffi-
ciency was on the basis of an abnormal response to one 
of the two reference standards for evaluating the integ-
rity of the HPA axis: ITT or overnight metyrapone test. 
The authors of the meta-analysis relied on individual 
study investigators to dichotomize the reference test 
results into adrenal function normal or adrenal insuf-
ficiency. The authors also pointed out that the SST 
lacks sensitivity in the presence of central adrenal 
insufficiency.
Here, we looked at cortisol levels checked at any time of 
the day (04.40–23.55) and did not ascertain a lower thresh-
old below which there was adrenocortical insufficiency 
Table 1 Baseline characteristics and cortisol results by short synacthen test (SST) result
Age Pass Borderline Fail Overall
Age (years) mean 54.8 53.2 64.3 52.9
 Range 16.8–100.3 30.1–81.1 32.2–78.9 16.8–100.3
SST result
All cases: n (%) 183 (81.3%) 12 (5.3%) 30 (13.4%) 225 (100%)
No steroids in previous 2 weeks n (%) 134 (91.8%) 4 (2.7%) 8 (5.5%) 146
Steroids taken in previous 2 weeks n (%) 41 (51.9%) 9 (11.4%) 29 (36.7%) 79
Pituitary disease, n (%) 50 (82.0%) 1 (1.6%) 10 (16.4%) 61
Autoimmune disorder 38 (74.5%) 2 (3.9%) 11 (21.6%) 51
Pass: 30-min cortisol 450 nmol/L or more. Borderline: 30-min cortisol 350–449 nmol/L. Fail: 30-min cortisol <350 nmol/L (see appendix for definition of autoimmune 
disorders).
Adrenocortical function assessment Michaelidou et al. 141
Fig. 1
Relation between random cortisol and 30-min postsynacthen cortisol for those not on steroid treatment (including inhaled corticosteroids) in the 
previous 2 weeks (a), for those with a history of steroid use in the previous 2 weeks (b) and for those with a history of the pituitary disease (irre-
spective of recent steroid use) (c). Data is shown as scatter plots with 6-hourly time bands denoted by different colored points. (a) Patients not on 
steroids for 2 weeks prior to the SST. One patient with random cortisol 200 nmol/L ‘failed’ the SST. (b) Patients on steroids in the 2 weeks prior 
to the SST. (c) Patients with a history of pituitary disease.
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on the basis of the SST. Our focus was on those cases that 
may not require an SST.
In 7.2% of cases, an adequate response was seen at 
60 min but not at 30 min. The 60-min cortisol, therefore, 
retains utility in ruling out adrenocortical insufficiency. 
Determination of the 60-min cortisol is done in some 
endocrine centers and was supported by the work of 
Chitale et al. [8]. The authors of that paper stated that 
individuals passing the SST only at 60 min tend to exhibit 
a ‘delayed response’ to exogenous adrenocorticotrophic 
hormone (ACTH) but, in essence, have normally func-
tioning adrenal glands. If their management was to be 
based solely on the 30-min sample, they would be com-
menced on unnecessary, long-term steroid replacement 
therapy.
In order to justify omitting the 60 min sample, the percent-
age of individuals with a ‘delayed response’ to synacthen 
would need to be as close to zero as possible. We and Chitale 
et al. [8] found that a significant percentage of subjects in 
both centers are at risk of misdiagnosis without the 60 min 
sample, so providing evidence for its value in improving the 
accuracy of diagnosis in the SST has been brought to light. 
We propose that there may be a subgroup of people who 
have a delayed response to synacthen in whom measure-
ment of the 60-min cortisol is helpful. Indeed, on the basis 
of our data, it may be advocated that the 60-min value is 
preferable to the 30-min value. This conclusion was also 
supported in a recent paper by Butt et al. [9], who looked 
at 849 people undergoing SSTs and reported that 9.5% of 
patients had a suboptimal response at 30 min, but reached 
the threshold value at 60 min.
Our aim with this relatively small series is to stimulate 
debate in terms of (1) when an SST needs to be arranged 
and (2) whether the 60-min level offers additional value. 
The SST is an expensive test in terms of hospital staff 
time – in most countries, the test is performed as a hos-
pital day case – and also entails significant inconvenience 
for the patient. The undertaking of less SSTs as a whole 
by application of the 200  nmol/L cut-point for random 
cortisol might well free up resource for measurement of 
the 60-min postsynacthen cortisol in terms of staff time. 
Certainly, a proportion of people passed on the basis of 
the 60-min cortisol when they would not have passed on 
the basis of the 30-min cortisol.
With regards to the interpretation of the SST result itself, 
concurrent factors, such as the taking of the oral contraceptive 
pill or HRT, may influence the results [10]. Immunoassays 
Table 2 Cortisol values (nmol/L) for patients not on steroid treat-
ment in the previous 2 weeks (n = 146) given as mean (range)
 Pass (n = 134) Borderline (n = 4) Fail (n = 8)
Random cortisol 206 (35–1202) 181 (181–181) 173 (92–367)
30-min cortisol* 732 (428–1643) 355 (355–355) 245 (37–345)
60-min cortisol** 845 (506–1889) 364 (364–364) 307 (38–348)
*P = 0.009 for pass vs. fail.**P = 0.005 for pass vs. fail.
Fig. 1
Continued.
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use different detection antibodies that provide results that 
may demonstrate significant bias between methods. For 
example, the low reference limit for cortisol 30 min after 
corticotropin stimulation ranges from 418 to 574  nmol/L 
(15.2–20.8 g/dL) [11,12]. The actual cut-point used in clini-
cal practice to make the diagnosis should be on the basis of 
assay-specific normative data. The laboratory providing the 
result should be able to provide the performance bias of the 
cortisol method in use. There is the possibility in the future 
of the application of an adjustment factor between different 
assays to facilitate national and international comparison as 
is done for some other analytes.
Traditionally, a peak cortisol concentration after acute 
stimulation with corticotropin exceeding 500  nmol/L 
(18 g/dL) is accepted as evidence for sufficient adreno-
cortical responsiveness [12–16], but studies advocating 
this level generally do not allude to the between assay 
differences. Importantly Erturk et al. [17] asserted some 
time ago that the baseline morning serum cortisol con-
centration has limited predictive power in differentiat-
ing between normal and impaired HPA function and that 
insulin-induced hypoglycemia is still the best indicator 
of the integrity of the response of the HPA axis to stress. 
Insulin-induced hypoglycemia is no longer practical in 
most hospital investigation units.
In a separate paper, Struja et al. [18] showed that basal 
cortisol levels ≤100 and ≥450 nmol/L, respectively, ruled 
in adrenocortical insufficiency and ruled out adrenocor-
tical insufficiency, abolishing the need for formal ACTH 
testing in such circumstances. Furthermore, Gasco et al. 
[19] reported that the cut-off of morning serum cortisol 
concentration that best predicted a deficient response 
to ITT was ≤126.4 nmol/L, while the cut-off of morning 
serum cortisol concentration that best predicted a normal 
response to ITT was >444.7 nmol/L [19].
In our study, there was a slight difference in the number 
of people deemed as a pass on the SST if baseline cortisol 
was 200 nmol/L or more between a 30-min cortisol cut-
off of 450 nmol/L (4/81 did not pass) vs. a 30-min serum 
cortisol cut-off of 500 nmol/L (6/81 did not pass).
In relation to strengths and weaknesses, we were able to 
access the clinical details on all the people undergoing an 
SST at our hospital over a 12-month period. All cortisol 
measurements were performed on the same assay plat-
form, and all the outpatient evaluations were carried out 
on our day ward. Our findings may have more weight for 
random cortisol measurements taken after 1500 h in view 
of the diurnal variation in serum cortisol levels. The pur-
pose of our paper is to assert (with evidence) that for any 
assay, there is a cut-point lower than 400 nmol/L for ran-
dom cortisol vs. likely adrenocortical insufficiency rather 
than precisely defining that cut-point. We recognize that 
there are differences between assay platforms and within 
assay platforms. For example, the Siemens Advia Centaur 
Fig. 2
Relation between random cortisol levels (nmol/L) and time of sample collection.
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platform as used here has a positive bias vs. mass spec-
trometry of 11–14%, whereas the Abbott Architect has a 
negative bias vs. mass spectrometry of −5.0 to −6.5%.
This study represents an evaluation in a real-world set-
ting. Hence, we did not have sufficient individuals with a 
measurement of ACTH to include this in our analysis, the 
decision as to whether to proceed to an SST was made by 
the clinician on the basis of laboratory recommendation. 
While caution is always the main consideration in terms 
of not missing adrenocortical insufficiency, in this retro-
spective analysis, we had no influence on which individ-
uals proceeded to an SST following the cortisol check. 
This paper must be seen as a ‘quasivalidation’ study. 
Nevertheless, our findings may help to guide clinician 
decision-making.
It should also be pointed out that the reason why 
there are very few random cortisol levels more than 
450  nmol/L in Fig.  1 is that our endocrinology ser-
vice advises that, unless there is clinical suspicion of 
adrenal insufficiency in cases where the random serum 
cortisol is 400  nmol/L or more, an SST is not indi-
cated. Furthermore, the random serum cortisol cut-off 
of 200 nmol/L or more is on the basis of the Siemens 
assay platform.
Conclusion
In conclusion, our findings suggest that if the random 
cortisol level is ≥200  nmol/L and the person was not 
on corticosteroid treatment in the previous 2  weeks, 
there may be no need to perform an SST. Exclusions 
include women on the COCP or on estrogen-contain-
ing HRT. In 7.2% of cases, an adequate response was 
seen at 60  min but not at 30  min. The 60-min corti-
sol, therefore, retains utility as a tool to assess adre-
nal insufficiency. Performing fewer ‘unnecessary’ SSTs 
would potentially free up resource on day units for the 
60-min test.
Any reduction in the number of ‘unnecessary’ SSTs will 
reduce hospital investigation costs and result in less incon-
venience for patients. Clearly, a larger study is required 
before any definitive conclusions can be drawn. Finally, 
standardization of assays in terms of the cortisol reference 
range for the SST must be a priority for laboratories.
A single measurement of serum cortisol carries the poten-
tial significantly to reduce the need for dynamic testing 
in the investigation of adrenal insufficiency
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What is known about this subject
• The short synacthen test (SST) is the most com-
monly performed investigation to assess suspected 
adrenocortical insufficiency. The criteria for when 
an SST should be performed is subject to debate.
• In the presence of adequate random serum corti-
sol, an SST may not be necessary.
What this paper adds
• We related random serum cortisol measurements 
taken between 04.40–23.55 h to the results of 225 
consecutive SST baseline and 30-/60-min cortisol 
performed over 12 months (225 SSTs) at a single 
center. We also looked at the value of measuring 
60-min as well as 30-min postsynacthen cortisol.
• Our findings suggest that if the random serum cor-
tisol level (at any time of the day) is ≥200 nmol/L, 
in individuals not on exogenous glucocorticoid 
therapy, and not taking any estrogen therapy at the 
time of the random cortisol check, there may be no 
need to perform an SST.
• The 60-min cortisol retains utility as part of the 
SST as it enables some people to avoid further 
testing who otherwise would have to undergo this.
Summary
• A single measurement of serum cortisol with care-
ful interpretation carries the potential significantly 
to reduce the need for dynamic testing in the 
investigation of adrenal insufficiency.
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Appendix 1: Autoimmune diseases
Arthropathies (rheumatoid arthritis, inflammatory 
arthropathy, ankylosing spondylitis) N = 12
Inflammatory bowel disease (Crohn's ulcerative colitis) 
N = 10
Autoimmune thyroid disease N = 9








Primary biliary cirrhosis N = 1
N = 4 patients had more than one autoimmune diagnosis
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